ACD backs Ultragenyx CTD therapy with $4 million commitment

The Association for Creatine Deficiencies has entered a venture philanthropy agreement with Ultragenyx Pharmaceutical to help fund clinical development of UX068 for Creatine Transporter Deficiency. The $4 million commitment is ACD’s largest research investment and aims to speed a potential treatment for a disease with no approved therapies.

Why it matters: - Creatine Transporter Deficiency is an ultra-rare genetic disorder with serious neurological and physical effects, and there are no approved treatments. - ACD’s $4 million commitment is designed to move UX068 into clinical trials faster and expand options for families affected by CTD. - The agreement adds another funding stream for creatine deficiency research and supports ACD’s broader effort to advance newborn screening and treatment development.

What happened: - The Association for Creatine Deficiencies announced a venture philanthropy agreement with Ultragenyx Pharmaceutical Inc. on July 2, 2026. - ACD will invest in the clinical development of UX068, an investigational small molecule therapy for CTD. - The total commitment is $4 million as the program progresses. - Ultragenyx and ACD will work through a joint steering committee to review progress and advance the program. - Emil Kakkis, Ultragenyx’s chief executive officer and president, said the partnership reflects a shared commitment to a new future for CTD and the urgency for treatments. - Kakkis delivered the keynote address at ACD’s 2026 CCDS Scientific & Patient Symposium on June 26 in Utah.

The details: - CTD deprives the brain and body of creatine, a molecule needed for cellular energy. - The condition can cause epilepsy, intellectual disabilities, speech and language delays, gastrointestinal complications, and low muscle tone. - ACD called the $4 million pledge to fund UX068 clinical trials the largest research investment in its history. - The commitment is a milestone for ACD’s Race for a Cure campaign, which launched in 2025 to accelerate high-impact research toward treatments for Cerebral Creatine Deficiency Syndromes. - Heidi Wallis, ACD’s executive director, said CTD families have waited long enough and that ACD is stepping in to share risk with partners and help therapies reach clinical trials. - ACD said it will continue funding multiple avenues of research for treatments and cures for all creatine deficiency disorders. - The Ultragenyx agreement follows ACD’s announcement last week of more than $1.1 million in Race for a Cure research awards to Johns Hopkins University, the University of California Berkeley, and Stanford University. - ACD said those awards are part of a broad effort to move multiple CTD and GAMT therapies toward the clinic.

Between the lines: - The funding model shows patient advocacy groups taking a more direct role in de-risking early-stage rare-disease drug development. - ACD is spreading bets across several research programs while making one unusually large commitment to a single CTD therapy. - The joint steering committee gives ACD a formal role in guiding progress, which can matter in rare disease programs where patient priorities and trial speed are critical.

What's next: - ACD’s next Race for a Cure goal is to raise $2 million by Dec. 31, 2026, to support this investment and other research efforts. - Any financial return ACD receives from philanthropic investments will be redirected to research, family support, and newborn screening for all three creatine deficiency syndromes. - ACD is asking supporters to give through Race for a Cure. - ACD also directs people to its main site for more information at more information.